Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

Home
/
update
/
details

Qiagen and Myriad Genetics Forge Partnership to Create Sequencing-Based HRD Kit

NextEdge Admin

01 Jun 2024

3 min 2 sec

Qiagen and Myriad Genetics have announced a significant development in their collaboration, aiming to create a globally distributable kit-based test for analyzing homologous recombination deficiency (HRD) status. This extension builds upon their prior master collaboration announced in October, wherein Qiagen will spearhead the development and distribution of HRD test kits outside the US. These kits are intended to serve as companion diagnostics, facilitating therapy decisions and improving patient outcomes.

The test kits will leverage Qiagen’s QiaSeq xHYB technology and Qiagen Digital Insight (QDI) informatics solution along with Myriad’s MyChoice CDx biomarkers. These next-generation sequencing-based kits will support research and companion diagnostics development in partnership with pharmaceutical collaborators. This collaboration aims to broaden the adoption and clinical indication expansion for MyChoice CDx, offering regulatory compliance and integration for clinical and companion diagnostic applications.

Myriad’s MyChoice CDx assay is a centralized testing service that evaluates HRD status by analyzing a tumor’s DNA repair capabilities, focusing on BRCA1 and BRCA2 gene mutations, and calculating a genome instability score (GIS). This assay aids in identifying ovarian cancer patients who may benefit from targeted treatments. The introduction of a distributable HRD test is expected to streamline therapy decisions, reduce costs, and shorten turnaround times compared to outsourced testing.

The MyChoice CDx assay, with its GIS score, can identify a significantly higher number of tumors with HRD compared to other methods, contributing to the advancement of personalized medicine. Approximately half of ovarian cancer tumors exhibit HRD, emphasizing the importance of expanding access to this assay for ensuring patients receive optimal treatments.

Aside from this collaboration, Myriad has similar agreements with Illumina, while Qiagen has established collaboration agreements with over 30 global pharmaceutical and biotech companies for companion diagnostics development and commercialization. These efforts collectively aim to enhance diagnostic capabilities, drive personalized medicine, and improve patient care outcomes on a global scale.